Scholar Info

Mark Kelley

Betty and Earl Herr Professor in Pediatric Onc Res

Professor, Departments of Pediatrics, Biochemistry & Molecular Biology and Pharmacology & Toxicology Associate Director, HB Wells Center for Pediatric Research Associate Director of Basic Science Research, Indiana University Simon Cancer Center Director, Program in Molecular Pediatric Oncology Chair, Preclinical Project Development Team, iCTSI


Cancer therapeutics of DNA repair targets

Mark R. Kelley, PhD has been part of the IU School of Medicine Department of Pediatrics since 1993 and is currently the Betty and Earl Herr Chair in Pediatric Oncology Research, Professor of Biochemistry and Molecular Biology, Professor of Pharmacology and Pediatrics, Associate Director for the Herman B Wells Center for Pediatric Research, and the Associate Director of Basic Science Research at the Indiana University Melvin and Bren Simon Cancer Center. He was formerly the Jonathan and Jennifer Simmons chair in Pediatrics, a position awarded to an investigator who is a strong proponent and contributor in the area of translational cancer research, which he held until 2008 when he was awarded the current Chair position. Dr. Kelley’s laboratory studies DNA repair genes involved in repairing base damage that occurs from oxidative and alkylation events in normal and tumor cells and following cancer treatments. Ongoing projects include: 1) Studying the multifunctional Ape1/Ref-1 protein structure/function in order to determine its redox and repair functions in normal and cancer cells such as ALL and pancreatic cancer, 2) Molecular targeted therapeutic approaches at members of the DNA base excision repair (BER) pathway, 3) Altering Ape1’s redox function and role in angiogenesis as a therapeutic approach for cancer and other indications, 4) Role of DNA repair genes in cognitive dysfunction (“chemobrain”) and peripheral neuropathy. He holds 10 patents related to the use of DNA repair targets for cancer therapy, is involved in two biotech start-up companies resulting from his discoveries. He is the Chief Scientific Founder of ApeX Therapeutics, an integrated drug development company built to leverage the APE1 target platform to produce new therapeutics to meet unmet needs in cancer and an officer in RetinoRX (RRX) which has licensed his IP to develop treatments for macular degeneration and other eye diseases. Because of his translational and basic research proficiency in this area, he has also been invited to serve on the consulting and scientific boards of Novus Biologicals, Littleton, CO; Pangene, Freemont, CA; and Semafore Pharmaceuticals, Inc. Thus far Dr. Kelley’s research has manifested in over 150 articles/27 reviews/chapters in peer reviewed journals. He also reviews for 15 national/international journals and sits on several journals’ editorial boards. He has been a reviewer for numerous national and international grant programs and throughout his career, has sustained an intimate involvement in NCI funding and programs. He currently serves as a study section member for the NCI-F awards. In 2006 Dr. Kelley spearheaded a multidisciplinary translational research group to facilitate basic research into clinical application and leverage institutional resources. This pilot program changed the grant review and funding award process for the IUSCC and became the model for the Project Development Teams created under the Indiana CTSI award.